Compare · BRKR vs HBIO
BRKR vs HBIO
Side-by-side comparison of Bruker Corporation (BRKR) and Harvard Bioscience Inc. (HBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and HBIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $8.66B, about 251.0x HBIO ($34.5M).
- Over the past year, BRKR is up 67.0% and HBIO is up 36.4% - BRKR leads by 30.7 points.
- BRKR has been more active in the news (19 items in the past 4 weeks vs 4 for HBIO).
- BRKR has more recent analyst coverage (22 ratings vs 2 for HBIO).
- Company
- Bruker Corporation
- Harvard Bioscience Inc.
- Price
- $56.86-0.22%
- $7.46-1.13%
- Market cap
- $8.66B
- $34.5M
- 1M return
- -5.30%
- +22.31%
- 1Y return
- +67.04%
- +36.36%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 19
- 4
- Recent ratings
- 22
- 2
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Harvard Bioscience Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
Latest BRKR
- Chief Accounting Officer Bures Thomas was granted 4,035 shares, increasing direct ownership by 126% to 7,233 units (SEC Form 4)
- President BMID Group Pusch Wolfgang sold $197,614 worth of shares (3,473 units at $56.90) and was granted 3,120 shares, decreasing direct ownership by 3% to 9,801 units (SEC Form 4)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N was granted 15,794 shares and covered exercise/tax liability with 2,724 shares, increasing direct ownership by 13% to 111,354 units (SEC Form 4) to cover taxes
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19, sold $115,200 worth of shares (2,000 units at $57.60) as part of a pre-agreed trading plan, was granted 14,443 shares and covered exercise/tax liability with 2,984 shares, increasing direct ownership by 9% to 134,806 units (SEC Form 4) (for tax liability)
- PRESIDENT & CEO Laukien Frank H was granted 29,463 shares and covered exercise/tax liability with 4,760 shares, increasing direct ownership by 0.06% to 38,507,043 units (SEC Form 4) to cover withholding tax
- PRESIDENT CALID Srega Juergen was granted 16,898 shares, increasing direct ownership by 11% to 174,625 units (SEC Form 4)
- PRES. & CEO, BRUKER BEST Prause Burkhard was granted 3,303 shares, increasing direct ownership by 13% to 28,461 units (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 1% to 123,347 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 4,838 shares, decreasing direct ownership by 0.01% to 38,482,340 units (SEC Form 4) (tax withholding)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 1,410 shares, decreasing direct ownership by 1% to 98,284 units (SEC Form 4) (for tax liability)
Latest HBIO
- SEC Form 10-Q filed by Harvard Bioscience Inc.
- Harvard Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Harvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Harvard Bioscience Announces Second Quarter 2026 Financial Results
- Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
- Director Eade Katherine A. was granted 16,556 shares, increasing direct ownership by 39% to 58,669 units (SEC Form 4)
- Director Snider William was granted 16,556 shares, increasing direct ownership by 52% to 48,556 units (SEC Form 4)
- Director Denelsky Stephen J was granted 16,556 shares, increasing direct ownership by 79% to 37,556 units (SEC Form 4)
- Director Gagnon Robert E. was granted 16,556 shares, increasing direct ownership by 151% to 27,556 units (SEC Form 4)
- Director Benson Seth Benjamin was granted 16,556 shares, increasing direct ownership by 151% to 27,556 units (SEC Form 4)